Arcus Biosciences, Inc.

This is the first human study testing the safety of an experimental drug called AB598 in people with advanced cancers. The trial will enroll 40 participants with various cancers including lung, stomach, bladder, and breast cancer to determine safe dosage levels and monitor side e…

This large Phase 3 trial is comparing a new combination of two immunotherapy drugs plus chemotherapy against the current standard treatment for advanced stomach and esophageal cancers. The study involves 1040 patients who haven't received prior treatment for their advanced cancer…

This large, late-stage trial is testing whether adding a new drug called quemliclustat to standard chemotherapy helps people with newly diagnosed metastatic pancreatic cancer live longer. It will compare the survival of 610 participants who receive either the new drug combination…

This is an early-stage safety study for a new drug called AB801, given alone or with other treatments, for people with advanced cancers that have stopped responding to available therapies. The main goal is to find a safe dose and understand the drug's side effects in about 91 par…

This study is testing whether combining two immunotherapy drugs (zimberelimab and domvanalimab) can help control advanced non-small cell lung cancer in people who haven't had prior treatment. The trial is for patients whose cancer has high levels of a specific marker called PD-L1…

This study is testing several new drug combinations, with and without standard chemotherapy, for people with advanced stomach, esophageal, or gastroesophageal junction cancers. The main goals are to see if these combinations are safe and if they can shrink tumors or slow the canc…

This early-stage study is testing the safety and best dose of a new four-drug combination for people with advanced pancreatic cancer. The treatment mixes a new drug (AB680) with an immunotherapy drug and two standard chemotherapy drugs. The main goal is to see how well patients t…